Hematology
Daga
$47,000
Har zuwa $200,000 ya danganta da cibiya
Tsawon lokaci na yau da kullum
20–50 days
Hada da gwaje-gwajen kafin tiyata
Asibitocin hadin gwiwa
1
An duba su don bayanan sakamako da takardar shaida
An bincika wannan abun ciki don daidaiton likitanci daga: Rodina Ainasoa, MD · Marubuciyar Likitanci & Sadarwar Lafiya
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of personalised cellular immunotherapy in which a patient's own T-cells are genetically engineered to recognise and target specific cancer cells. It is currently FDA-approved for a defined set of relapsed or treatment-resistant blood cancers — including certain B-cell lymphomas, B-cell acute lymphoblastic leukaemia (ALL), and multiple myeloma — for patients who have already tried standard therapies; response and remission depend on the specific diagnosis and are determined case-by-case by a haematology-oncology specialist. China is a leader in CAR-T manufacturing with domestically approved products (including Relma-cel and Yescarta/Fosun Kite) at a fraction of US prices. India offers the homegrown NexCAR19 product, priced far below imported alternatives, through JCI-accredited centres including Christian Medical College Vellore, though international-patient package costs (covering the full collection-to-monitoring pathway) run higher than the domestic drug price alone.
Ana daidaita al'amarinku da cibiya bisa bayanan sakamako na likitanci, ba talla ba. Muna tsara kowane mataki — daga gwaje-gwajen kafin tiyata zuwa biye-biye bayan jiyya — tare da mai tsara kulawa na musamman.
CAR-T Cell Therapy
An tsara daga
ko aiko mana sako a kan WhatsApp
Ba a bukatar alkawari. Ba a taba raba bayananku da wasu jam'iyyu ba.
"Maganin CAR-T" ya ƙunshi kayayyaki daban-daban, kowanne yana da amincewar FDA daban, suna nufin sunadarai daban-daban don cutar kansar jini daban-daban. Ga yadda manyan iyalai biyu na kayayyaki suke kwatanta.
| Sigar | CAR-T Mai Nufin CD19 | CAR-T Mai Nufin BCMA |
|---|---|---|
| Alamomin da aka amince da su | Lymphoma na babban salula-B da ta koma ko ba ta amsa magani ba (ciki har da DLBCL), wasu lymphoma na salula-B da ba na Hodgkin ba, da leukemia na lymphoblastic na salula-B mai tsanani da ta koma ko ba ta amsa magani ba (ALL), gabaɗaya bayan an gwada maganin gargajiya amma ya kasa. | Myeloma da yawa da ta koma ko ba ta amsa magani ba ga marasa lafiya da suka riga suka karɓi jerin magunguna da yawa a baya. |
| Antigen da ake nufi | CD19, sinadari da ake samu a salula-B na kansa da lafiyayye. | Antigen na girman salula-B (BCMA), sinadari da ake nunawa a salula na plasma. |
| Misalan kayayyaki da FDA ta amince da su | Axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, da lisocabtagene maraleucel, bisa ga amincewar FDA. | Idecabtagene vicleucel da ciltacabtagene autoleucel, bisa ga amincewar FDA. |
| Cutar sakin cytokine (CRS) | Ana ba da rahoton wannan a wata hanya ga yawancin marasa lafiya, tare da mummunar CRS (mataki na 3 ko fiye) a kusan 6-10% dangane da takamaiman kaya, bisa ga bayanan gwajin asibiti da aka buga da bayanan duniya na gaske. | Hakanan ana ba da rahoton hakan ga yawancin marasa lafiya, ko da yake jerin bayanan duniya na gaske da aka buga sun ba da rahoton mummunar CRS (mataki na 3 ko fiye) a ƙarami kaso, gabaɗaya ƙasa da 10%, bisa ga bincike na ƙasa da ASH ta buga. |
| Guba ga jijiyoyi (ICANS) | An ba da rahoton ICANS na kowane mataki a kusan 16-33% na marasa lafiya dangane da kaya, tare da munanan lokuta a ƙaramin rukuni, bisa ga bincike-bincike da aka duba. | Gabaɗaya ana ba da rahoton ICANS na kowane mataki ƙasa da yawa fiye da kayayyakin da suke nufin CD19, a kusan kashi 10-19% a cikin jerin da aka buga, bisa ga karatuttukan da aka duba da bayanan duniya na gaske. |
Bayanin da ke ƙasa yana nuna tsarin gaba ɗaya da ake raba tsakanin kayayyakin CAR-T da FDA ta amince da su. Ƙungiyar ku ta hematology-oncology za ta tabbatar da tsarin da jadawalin da suka dace da kaya da ganewar cutar ku.
Leukapheresis (Tattara salula-T)
Ana zana jini a wuce ta na'ura mai raba salula wanda ke tattara farin salula na jini masu ɗauke da salula-T, sannan a mayar da sauran sassan jini ga mai haƙuri. Aikin yakan ɗauki sa'o'i da yawa a matsayin marasa lafiya na waje.
Kera da injiniyar kwayoyin halitta
Ana turo salula-T da aka tattara zuwa wani wurin kera na musamman, inda ake yin injiniyar kwayoyin halitta don su nuna mai karɓar antigen na chimeric, a ƙara su a yawa, sannan a gwada inganci kafin a dawo da su. Wannan tsari yakan ɗauki kimanin makonni 2 zuwa 4, ko da yake lokaci na iya bambanta bisa ga kaya da cibiyar kerawa.
Chemotherapy na lymphodepleting
A cikin kwanaki kafin allurar kai tsaye, ana ba da ɗan gajeren kwas na chemotherapy (galibi kwana 3) don rage lymphocytes da ke akwai na mai haƙuri, wanda ke haifar da yanayi da ke tallafawa yaɗuwar salula-CAR-T da aka allura.
Allurar salula-CAR-T da sa ido na farko
Ana allurar salula-CAR-T da aka yi wa injiniyar kwayoyin halitta ta jijiya, galibi a ziyara ɗaya. Sannan ana sa wa marasa lafiya ido sosai a asibiti don alamun farko na cutar sakin cytokine (CRS) ko guba ga jijiyoyi (ICANS), waɗanda galibi kan bayyana a cikin makon farko zuwa na biyu bayan allurar.
Lokacin haɗarin mafi girma na cutar sakin cytokine (CRS) da guba ga jijiyoyi (ICANS), duka biyu galibi kan bayyana a cikin wannan lokacin. Marasa lafiya suna zama a asibiti ko ƙarƙashin kula na kusa na waje domin ƙwararrun ƙungiyoyi su iya shiga tsakani cikin sauri idan alamu suka bayyana.
Ana shawartar yawancin waɗanda suka karɓi CAR-T su zauna kusa da cibiyar magani na kimanin makonni 4 bayan allurar, saboda haɗarin gubar da ke jinkirin bayyana, don su iya dawowa cikin sauri don bincike idan an buƙata.
Ƙidayar jini da aikin garkuwar jiki suna dawowa a hankali a wannan lokacin; ƙarancin farin salula na jini da antibodies na iya ƙara haɗarin kamuwa da cuta, don haka ana sa wa marasa lafiya ido don cytopenias kuma za su iya samun magungunan tallafi idan an buƙata.
Bibiyar na dogon lokaci tana ci gaba da sa ido kan yadda cuta take amsawa da dawowar garkuwar jiki, tare da sa ido na rayuwa gaba ɗaya kan haɗarin da ba kasafai ake samu ba na sabbin cutar kansa na salula-T, bisa ga jagorar FDA ta yanzu don duk kayayyakin CAR-T da aka amince da su.
Tushen: FDA; National Cancer Institute; karatuttukan asibiti da na duniya na gaske da American Society of Hematology ta buga. Warkewar kowane mutum ta bambanta kuma ƙungiyar hematology-oncology da ke kula da ku ce ke jagoranta.
Haɗari da Iyakoki da Aka Sani
Tushen: FDA; National Cancer Institute; bincike na ƙasa da na duniya na gaske da American Society of Hematology ta buga. Babu wani aiki da ba shi da haɗari; ƙungiyar hematology-oncology da ke kula da ku za ta duba halin ku na musamman.
Bitar shari'a ta nesa daga hematology-oncology
Raba rahotannin cutar ku, tarihin magani na baya, hoto, da duk wani gwajin kwayoyin halitta ko antigen da aka riga aka yi. Ƙungiyar mu ta tsarawa za ta aika da shari'ar ku don bitar farko ta ƙwararru don sanin ko ganewar cutar ku da nau'inta suna cikin alamomin CAR-T da FDA (ko wata hukumar yanki) ta amince da su a yanzu.
Tabbatar da cancanta da haɗawa da cibiya
Ƙwararren hematology-oncology ko maganin salula ne kaɗai zai iya tabbatar da cancanta, dangane da nau'in cutar kansar ku, nunin antigen, jerin magunguna na baya, da aikin gabobi. Bayan tabbatarwa, muna haɗa ku da cibiyar maganin CAR-T da aka amince da ita mai ƙwarewa a kayan ku da alamar cutar ku.
Kimanin kuɗi da shirin tafiya
Saboda bukatun kera da sa ido sun dogara da mutum, ana bayar da kimanin kuɗi da aka haɗa — wanda ya haɗa da leukapheresis, kerawa, chemotherapy na lymphodepleting, allura, da sa ido a asibiti — bayan an duba shari'ar ku kawai. Muna kuma shirya wa zaman dogon lokaci kusa da cibiyar da waɗannan magunguna ke buƙata.
Magani da lokacin sa ido na wajibi na ~makonni 4
Bayan leukapheresis da jiran kerawa, kuna dawowa don chemotherapy na lymphodepleting, allura, da sa ido a asibiti na CRS da ICANS. Yawancin cibiyoyi suna buƙatar marasa lafiya su zauna kusa da asibiti na kimanin makonni 4 bayan allurar saboda haɗarin matsalolin da za su iya bayyana daga baya.
Bibiya da ci gaba da kulawa
Kafin ku tashi, ana raba taƙaitaccen bayanin sallamawa, jadawalin sa ido mai gudana, da bayanan tuntuɓar ƙwararre da likitan hematology-oncology naku a gida domin ya iya ci gaba da sa ido kan ƙidayar jini, sarrafa haɗarin kamuwa da cuta, da bibiya na dogon lokaci, ciki har da sa ido na rayuwa gaba ɗaya kan sabon cutar kansa da FDA ta ba da shawara.
Matsakaicin farashi da aka tsara a fadin cibiyoyinmu na hadin gwiwa. Farashin karshe ya danganta da tsananin yanayi da asibitin da aka zaba.
| Kasa | Matsakaicin farashi | idan aka kwatanta da mafi araha |
|---|---|---|
🇮🇳 India New Delhi · Chennai · Bengaluru · Hyderabad · Mumbai · Kochi | $65,000 | —chevron_right |
🇨🇳 China Shanghai · Beijing · Hainan (Boao) | $150,000 | +131%chevron_right |
Farashi kimantawa ne kuma yana bambanta bisa ga cikakkun bayanan aikin, asibiti, da tsananin yanayin likita. Nemi kimar musamman don al'amarinku.
Faridabad, India
Mafi babbar asibiti mai zaman kansa a Asiya — gadaje 2,600, dakunan tiyata 64, fannonin likitanci 81 a filin kadada 130 a Delhi NCR. An amince da NABH da NABL. Cibiyoyin kwarewa a oncology, tiyata ta zuciya, BMT, dashen gaɓoɓi, kimiyyar jijiya, da IVF.
800+
Likitoci Kwararru
2,600+
Gadaje
CAR-T is currently approved for relapsed or refractory large B-cell lymphoma (including DLBCL), follicular lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukaemia (ALL), and multiple myeloma after prior lines of therapy. Eligibility depends on your specific cancer subtype, prior treatment history, molecular markers (e.g., CD19, BCMA expression), and performance status. Our partner centres will review your pathology reports, treatment history, and imaging to determine candidacy before you travel.
Babu kudi. Babu alkawari.
Asibitocinmu na hadin gwiwa ne suke biyanmu — ba majinyata ba. Kuna samun daidaita likitanci mai zaman kansa, bayyana farashi, da cikakken tsari ba tare da kudi a kanku ba.
